Implementation of Teledermoscopy and Artificial Intelligence

Condition(s) studied

Investigational drug(s) / intervention(s)

Diagnostic algorithms: Assessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case.

Study summary

The study has 2 parts. Part 1 will investigate the effects of introducing teledermoscopy in clinical practice, more specifically the change in referral patterns, the risk of undetected skin cancers and the effect on diagnostic accuracy in general practitioners.

Part 2 will investigate how to introduce artificial intelligence (AI) within teledermocsopy. In this study the investigators will measure the diagnostic accuracy of teledermoscopic assessors that had access to the results of artificial intelligence algorithm compared to those who did not.

Data will be collected through teledermoscopic referrals, patient records, national registries and questionnairs.

Eligibility

Primary outcome measure(s)

• Effect on referral patterns — 2 years
  Measure how referral patterns are affected by the introduction of teledermoscopy
• Effect on diagnostic accuracy due to availability of artificial intelligence — 8 years
  Measuring if the diagnostic accurcy differs depending on if physician can see the results of the artificial intelligence.
• Risk of undetected skin cancer — 2 years
  Measuring if the risk of undetected skin cancer increases with the use of teledermoscopy
• Artificial intelligence timing and effect on diagnostic accuracy and willingness to rethink the preliminary diagnosis — 8 years
  Measuring if the diagnostic accuracy and the willingness to reconsider the preliminary diagnosis differs according to when in the process a physician is presented with the results of the artificial intelligence

Trial sites (1)

More Region Skane trials in Sweden

Other trials for the same condition